A review of 75 adalimumab clinical trials in adult and pediatric patients demonstrated low rates of inflammatory bowel disease adverse events, according to data published in Arthritis Care & Research.

“Adalimumab is approved for the treatment of 15 indications worldwide, including adult and pediatric Crohn’s disease and adult ulcerative colitis,” Dirk Elewaut, MD, PhD, of Ghent University, in Belgium, and colleagues wrote. “Therefore, it may be postulated that exacerbations of existing or new-onset IBD are rare events in patients treated with adalimumab for non-IBD

Full Article: https://www.healio.com/rheumatology/rheumatoid-arthritis/news/online/e13f2205-3421-4807-9975-c589e84c510b/adalimumab-trials-show-low-rate-of-ibd-adverse-events